ZURICH (Reuters) – Novartis AG said on Tuesday Kesimpta (ofatumumab) has won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.
The Swiss drugmaker is developing and marketing the product under a license agreement with Genmab.
(Reporting by Michael Shields; editing by Brenna Hughes Neghaiwi)
QB Jaden Rashada transfers to Georgia after leaving Arizona State
Charlie Woods, son of Tiger, shoots 81 in local qualifier and fails in bid to play in US Open
Massive policing for Paris Olympics to include security checks for some of the capital’s residents
USA Track & Field expands its maternity policy to give athletes more time to work their way back
NFL Draft Latest: The Bears are up, with Caleb Williams expected to go No. 1
Fed plan to rebuild Pacific sardine population was insufficient, California judge finds
Net neutrality restored as FCC votes to regulate internet providers
Burkina Faso’s army massacred over 200 civilians in a village raid, Human Rights Watch says
Tennessee lawmakers OK bill criminalizing adults who help minors receive gender-affirming care
Hamas again raises the possibility of a 2-state compromise. Israel and its allies aren’t convinced
Minneapolis smokers to pay some of the highest cigarette prices in US with a $15 per-pack minimum
UN report says 282 million people faced acute hunger in 2023, with the worst famine in Gaza
Malaria is still killing people in Kenya, but a vaccine and local drug production may help
US births fell last year, marking an end to the late pandemic rebound, experts say
